Zacks Research Issues Positive Outlook for Integer Earnings

Integer Holdings Co. (NYSE:ITGR) – Research analysts at Zacks Research increased their Q1 2025 EPS estimates for Integer in a research note issued to investors on Thursday, December 5th. Zacks Research analyst D. Dey now forecasts that the medical equipment provider will earn $1.31 per share for the quarter, up from their previous estimate of $1.30. The consensus estimate for Integer’s current full-year earnings is $5.33 per share. Zacks Research also issued estimates for Integer’s Q2 2025 earnings at $1.43 EPS, Q3 2025 earnings at $1.55 EPS, Q4 2025 earnings at $1.68 EPS, FY2025 earnings at $5.97 EPS and FY2026 earnings at $6.59 EPS.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.07. The business had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.27 earnings per share.

Several other equities research analysts have also weighed in on ITGR. Benchmark increased their price objective on shares of Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Truist Financial decreased their price objective on Integer from $150.00 to $147.00 and set a “buy” rating for the company in a report on Friday, October 25th. Citigroup boosted their price target on shares of Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. KeyCorp boosted their price target on shares of Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Finally, Bank of America raised their price objective on shares of Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Integer currently has a consensus rating of “Moderate Buy” and an average target price of $142.00.

Integer Trading Up 0.1 %

Shares of NYSE ITGR opened at $139.39 on Monday. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The stock’s 50 day moving average price is $132.63 and its two-hundred day moving average price is $125.17. Integer has a 52-week low of $86.42 and a 52-week high of $142.76. The stock has a market capitalization of $4.68 billion, a P/E ratio of 43.02, a PEG ratio of 2.02 and a beta of 1.12.

Institutional Investors Weigh In On Integer

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Contravisory Investment Management Inc. raised its position in shares of Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 80 shares during the last quarter. Huntington National Bank lifted its position in Integer by 8,933.3% during the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 268 shares during the period. Quest Partners LLC boosted its stake in shares of Integer by 3,688.9% in the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 332 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Integer by 60.9% during the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 142 shares during the last quarter. Finally, Innealta Capital LLC acquired a new position in Integer in the second quarter valued at approximately $110,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.